A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects.

Trial Profile

A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANB020 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs ANB 020 (Primary) ; ANB 020 (Primary)
  • Indications Asthma; Atopic dermatitis; Peanut hypersensitivity
  • Focus Adverse reactions; First in man
  • Sponsors AnaptysBio
  • Most Recent Events

    • 08 Mar 2017 According to an AnaptysBio media release, data were presented at American Academy of Allergy, Asthma and Immunology (AAAAI) 2017 Annual Meeting.
    • 08 Mar 2017 According to an AnaptysBio media release, data were presented at the 2017 American Academy of Dermatology (AAD) Annual Meeting.
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top